"Malaysia Pharmaceuticals & Healthcare Report Q2 2011" now available at Fast Market Research

Fast Market Research recommends "Malaysia Pharmaceuticals & Healthcare Report Q2 2011" from Business Monitor International, now available
Spread the Word
Listed Under

* Pharmaceutical
* Malaysian
* Healthcare
* Cagr
* Bioequivalence
* Standards
* Tightening
* Drug
* Generics

* Health
* Medical
* Research

* Massachusetts - US

April 22, 2011 - PRLog -- Malaysia's pharmaceutical market potential is likely to be fulfilled in the longer term. For the time being, we view the market as a moderately attractive regional prospect. In BMI's Business Environment Ratings (BER) matrix for Q211, Malaysia remains placed eighth, out of the 17 markets surveyed. The key attractions of the Malaysian pharmaceutical market over the longer term will continue to be the government's encouragement of the biotechnology sector, the improving regulatory environment and the country's economic development, which will allow for higher public as well as private expenditure on pharmaceuticals. On the other hand, per-capita pharmaceutical consumption is quite low, especially due to the high out-of-pocket payment levels, which make the market vulnerable to economic downturns.

The market is based on a strong domestic generics sector and imports of branded and patented medicines (mostly from the US, Japan and Germany). Pharmaceutical spending represented an estimated 0.62% of GDP in 2010. Through to 2015, the Malaysian drug market, valued at around MYR4.57bn (US$1.40bn) in 2010, is expected to post a compound annual growth rate (CAGR) of 6.93% in local currency terms, supported by demographic and economic changes as well as by calls to improve access to medical services through the implementation of the National Healthcare Financing Scheme. This momentum is expected to be maintained over the following five years, with the 2010-2020 CAGR also coming in at 6.93%. Generics will be the best performing segment, posting a 9.25% CAGR to 2020.

The above outlook is supported by development such as the announcement that the Malaysian government is looking to raise quality and technical standards in the local pharmaceutical industry by tightening bioequivalence rules. The government will implement new regulations by 2012, under which all generic drugs submitted for approval in the country will have to present bioequivalence to a selected branded comparator product. According to Health Minister Dato' Sri Liow Tiong Lai, the regulations will bring the local pharmaceutical industry in line with international standards, allowing exports to an increasing number of markets.

However, while we expect the Malaysian economy to continue expanding steadily, we are concerned at the looming risk of a severe double-dip slowdown in China, where the recent spate of monetary tightening measures introduced by Beijing to stem the Chinese property bubble could eventually strangle the region's economic recovery, affecting our forecasts for the pharmaceutical sector. Despite having revised our 2010 Malaysian growth forecast to 6.4% in 2010 (from 4.9% previously), we believe regional weakness led by China will force Malaysia's real GDP growth to slow substantially to 3.4% in 2011, which will weigh on government finances and healthcare expenditure as a whole.

For more information or to purchase this report, go to:
-  http://www.fastmr.com/prod/149654_malaysia_pharmaceutical...

Partial Table of Contents:

SWOT Analysis
- Malaysia Pharmaceuticals And Healthcare Industry SWOT
- Malaysia Political SWOT
- Malaysia Economic SWOT
- Malaysia Business Environment SWOT
Pharmaceutical Business Environment Ratings
- Table: Asia Pacific Pharmaceutical Business Environment Ratings For Q211
- Rewards
- Risks
Malaysia - Market Summary
Regulatory Regime
- Bioequivalence
- Pharmaceutical And Medical Advertising
- Labelling Requirements
- Recent Regulatory Developments
- Intellectual Property Regime
- Counterfeit Pharmaceuticals
- Compulsory Licensing
- Free Trade Agreements
- Pricing And Reimbursement
Industry Trends And Developments
- Epidemiology
- Table: 10 Leading Causes Of Death In Ministry of Health Hospitals, 2005
- Non-Communicable Disease
- Communicable Disease
- Healthcare Sector
- Healthcare Sector Funding
- Medical Tourism
- Biotechnology And Research
- Table: Key Points Of The Malaysian National Biotechnology Policy
- Table: The Benefits Of Conducting Biotechnology Research In Malaysia
- Recent Biotechnology Developments
- Clinical Trials
- Recent Developments in the Clinical Trials Industry
- Medical Devices
- Leading Medical Device Players
- Recent Developments In The Medical Devices Industry
Industry Forecast Scenario
- Overall Market Forecast
- Table: Pharmaceutical Sales Indicators 2007-2015
- Key Growth Factors - Industry
- Table: Healthcare Expenditure Indicators 2007-2015
- Table: Government Healthcare Expenditure Indicators 2007-2015
- Table: Private Healthcare Expenditure Indicators 2007-2015
- Key Growth Factors - Macroeconomic
- Table: Malaysia - Economic Activity, 2006-2015
- Prescription Drug Market Forecast
- Table: Prescription Drug Sales Indicators 2007-2015
- Patented Drug Market Forecast
- Table: Patented Drug Market Indicators 2007-2015
- Generic Drug Market Forecast
- Table: Generic Drug Sales Indicators 2007-2015
- OTC Medicine Market Forecast
- Table: OTC Medicine Sales Indicators 2007-2015
- Medical Device Market Forecast
- Table: Medical Devices Sales Indicators 2007-2015
- Pharmaceutical Trade Forecast
- Table: Exports and Imports Indicators 2007-2015

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=1496...

About Business Monitor International

Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets.  BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports.  Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including in-depth quarterly Country Forecast Reports.  View more research from Business Monitor International at http://www.fastmr.com/catalog/publishers.aspx?pubid=1010

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

# # #

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
Email:***@fastmr.com Email Verified
Tags:Pharmaceutical, Malaysian, Healthcare, Cagr, Bioequivalence, Standards, Tightening, Drug, Generics
Industry:Health, Medical, Research
Location:Massachusetts - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse

Like PRLog?
Click to Share